CDER New: 9/16/2026

The approvals listed below may not be comprehensive. For the most current information, view the full listing of all approvals at Drugs@FDA.

What's New Related to Drugs

Updated Monday through Friday

  • Current and Resolved Drug Shortages and Discontinuations Reported to FDA
  • Drug Firm Annual Registration Status
  • Drug Firm Annual Registration Status Download File
  • National Drug Code Directory
  • NDC Unfinished Drugs Excluded Database File
  • NDC Database Excluded Packages and Products
  • Wholesale Distributor and Third-Party Logistics Providers Reporting
  • Drug Establishments Current Registration Site
  • Drugs@FDA Data Files 

Updated Biweekly

  • Competitive Generic Therapy Approvals

September 15, 2026

  • Public Notifications:
    • LUZE Fit Intensity may be harmful due to hidden ingredient
    • Beauty 911 may be harmful due to hidden ingredient
    • DEEP may be harmful due to hidden ingredient
  • Drug Safety Communication: FDA Approves Additional Information in Labeling for Kybella (Deoxycholic Acid) Injection Warning of Adverse Reactions Associated with Unapproved Use

September 11, 2026

  • FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy
  • Orange Book
    • Approved Drug Products with Therapeutic Equivalence Evaluations
    • Orange Book Current Cumulative Supplement (updated)
    • Additions/Deletions for Prescription and OTC Drug Product Lists (updated)
    • Orange Book Data Files (compressed) (updated)
    • Reference Listed Drugs by ANDA Reference Standard List (updated)
    • Orange Book Patent Listing Dispute List (updated)
  • FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system

This report displays final approvals and tentative approvals of original and supplemental applications for the two days beginning on the earliest date listed below. Some approvals may be added to the Drugs@FDA database after this time span. For comprehensive approval reports, please use the monthly "All Approvals" report on Drugs@FDA.

September 15, 2026

Drug Name and
Application Number
Active Ingredient Dosage Form/ Route Submission Company Submission Classification Submission Status
Amnesteem
ANDA #075945
Isotretinoin Capsule; Oral SUPPL-45 Mylan Pharms Inc Labeling Approved
Amnesteem
ANDA #075945
Isotretinoin Capsule; Oral SUPPL-45 Mylan Pharms Inc Labeling Approved
Pramipexole Dihydrochloride
ANDA #090241
Pramipexole Dihydrochloride Tablet; Oral SUPPL-6 Chartwell Rx Labeling Approved
Letrozole
ANDA #090292
Letrozole Tablet; Oral SUPPL-1 Actavis Totowa Labeling Approved
Letrozole
ANDA #090292
Letrozole Tablet; Oral SUPPL-1 Actavis Totowa Labeling Approved
Milnacipran Hydrochloride
ANDA #207399
Milnacipran Hydrochloride Tablet ORIG-1 Strides Pharma Global Pte Limited   Approved
Milnacipran Hydrochloride
ANDA #210944
Milnacipran Hydrochloride Tablet; Oral ORIG-1 Macleods Pharms Ltd   Approved
Garzulys
BLA #761497
Insulin Aspart-Fsan Pen; Prefilled ORIG-2 Emerge Bioscience Pte. Ltd.   Approved
Garzulys
BLA #761497
Insulin Aspart-Fsan Vial; Multidose ORIG-2 Emerge Bioscience Pte. Ltd.   Approved

September 14, 2026

Drug Name and
Application Number
Active Ingredient Dosage Form/ Route Submission Company Submission Classification Submission Status
Methadone Hydrochloride
ANDA #040088
Methadone Hydrochloride Concentrate; Oral SUPPL-33 Vistapharm Llc Labeling Approved
Methadone Hydrochloride
ANDA #040088
Methadone Hydrochloride Concentrate; Oral SUPPL-33 Vistapharm Llc Labeling Approved
Methadone Hydrochloride
ANDA #040088
Methadone Hydrochloride Concentrate; Oral SUPPL-33 Vistapharm Llc Labeling Approved
Colistimethate Sodium
ANDA #201365
Colistimethate Sodium Injectable; Injection SUPPL-6 Sagent Pharms Inc Labeling Approved
Primaquine Phosphate
ANDA #203924
Primaquine Phosphate Tablet; Oral SUPPL-2 Alvogen Labeling Approved
Primaquine Phosphate
ANDA #204476
Primaquine Phosphate Tablet; Oral SUPPL-7 Unichem Labeling Approved
Itraconazole
ANDA #205080
Itraconazole Capsule; Oral SUPPL-20 Amneal Pharms Labeling Approved
Itraconazole
ANDA #206741
Itraconazole Capsule; Oral SUPPL-22 Alembic Labeling Approved
Itraconazole
ANDA #206741
Itraconazole Capsule; Oral SUPPL-22 Alembic Labeling Approved
Tagrisso
NDA #208065
Osimertinib Mesylate Tablet; Oral SUPPL-35 Astrazeneca Efficacy Approved
Tagrisso
NDA #208065
Osimertinib Mesylate Tablet; Oral SUPPL-35 Astrazeneca Efficacy Approved
Tagrisso
NDA #208065
Osimertinib Mesylate Tablet; Oral SUPPL-36 Astrazeneca Labeling Approved
Doxycycline Hyclate
ANDA #211343
Doxycycline Hyclate Tablet; Oral SUPPL-10 Changzhou Pharm Labeling Approved
Clobazam
ANDA #211711
Clobazam Tablet; Oral SUPPL-7 Micro Labs Manufacturing (CMC) Approved
Clobazam
ANDA #211711
Clobazam Tablet; Oral SUPPL-7 Micro Labs Manufacturing (CMC) Approved
Clobazam
ANDA #211711
Clobazam Tablet; Oral SUPPL-7 Micro Labs Manufacturing (CMC) Approved
Evrysdi
NDA #213535
Risdiplam For Solution; Oral SUPPL-18 Genentech Inc Labeling Approved
Beclomethasone Dipropionate
ANDA #214418
Beclomethasone Dipropionate Aerosol, Metered; Inhalation ORIG-1 Aurolife Pharma Llc   Approved
Haloperidol
ANDA #218210
Haloperidol Tablet; Oral ORIG-1 Ajanta Pharma Ltd   Approved
Bexlutry
NDA #218525
Lutetium Lu 177 Donatate Injectable; Injection ORIG-1 Curium Type 5 - New Formulation or New Manufacturer Approved
Evrysdi
NDA #219285
Risdiplam Tablet; Oral SUPPL-3 Genentech Inc Labeling Approved
Epinephrine
ANDA #219832
Epinephrine Solution; Intramuscular, Intravenous, Subcutaneous ORIG-1 Zydus Pharms   Approved
Letrozole
ANDA #220438
Letrozole Tablet; Oral ORIG-1 Zydus Lifesciences   Approved
feedtwitterfacebookyoutubeflickr

Manage Subscriptions  |  Unsubscribe All  |  Help


This email was sent to Esdek@podam.pl using Granicus Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA
Granicus Communications logo